First National Bank Trust Co Of Newtown Lowers stake in Baxter International Inc (BAX)

Baxter International Inc (BAX) : First National Bank Trust Co Of Newtown reduced its stake in Baxter International Inc by 0.44% during the most recent quarter end. The investment management company now holds a total of 33,730 shares of Baxter International Inc which is valued at $1,573,505 after selling 150 shares in Baxter International Inc , the firm said in a disclosure report filed with the SEC on Jul 6, 2016.Baxter International Inc makes up approximately 0.48% of First National Bank Trust Co Of Newtown’s portfolio.

Other Hedge Funds, Including , Bnp Paribas Arbitrage Sa boosted its stake in BAX in the latest quarter, The investment management firm added 2,013,786 additional shares and now holds a total of 2,281,030 shares of Baxter International Inc which is valued at $106,410,050. Baxter International Inc makes up approx 0.47% of Bnp Paribas Arbitrage Sa’s portfolio. Stock Yards Bank Trust Co added BAX to its portfolio by purchasing 4,591 company shares during the most recent quarter which is valued at $208,018. Baxter International Inc makes up approx 0.03% of Stock Yards Bank Trust Co’s portfolio. Cullinan Associates Inc sold out all of its stake in BAX during the most recent quarter. The investment firm sold 25,195 shares of BAX which is valued $1,145,113.

Baxter International Inc closed down -0.16 points or -0.34% at $46.49 with 44,82,477 shares getting traded on Monday. Post opening the session at $46.87, the shares hit an intraday low of $46.37 and an intraday high of $46.9 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Baxter International Inc reported $0.36 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Apr 26, 2016. Analyst had a consensus of $0.29. The company had revenue of $2375.00 million for the quarter, compared to analysts expectations of $2351.22 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.00 EPS.

Many Wall Street Analysts have commented on Baxter International Inc. Baxter International Inc was Resumed by JP Morgan to “Neutral” on Jun 6, 2016. Company shares were Reiterated by RBC Capital Mkts on Apr 27, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 47 from a previous price target of $40 .Baxter International Inc was Upgraded by Piper Jaffray to ” Overweight” on Apr 14, 2016.

Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment which include three commercial franchises: Hemophilia BioTherapeutics and BioSurgery and Medical Products segment which include four commercial franchises: Fluid Systems Renal Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute blood-related conditions and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets premixed drugs and drug-reconstitution systems pre-filled vials and syringes for injectable drugs IV nutrition products infusion pumps and inhalation anesthetics. Its products are used in hospitals kidney dialysis centers and nursing homes among others.

Leave a Reply

Baxter International Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Baxter International Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.